OX 914

Drug Profile

OX 914

Alternative Names: OX914

Latest Information Update: 09 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orexo
  • Class Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis

Most Recent Events

  • 06 Mar 2012 Discontinued - Phase-II for Seasonal allergic rhinitis in Sweden (PO)
  • 06 Mar 2012 Discontinued - Preclinical for Asthma in Sweden (PO)
  • 06 Mar 2012 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top